Literature DB >> 17214319

Revisiting the role of p53 in primary and secondary glioblastomas.

Julie Nagpal1, Amrith Jamoona, Nicholas D Gulati, Avinash Mohan, Alex Braun, Raj Murali, Meena Jhanwar-Uniyal.   

Abstract

Glioblastoma multiforme (GBM) develops from astrocytes and is the most aggressive primary cancer in humans. Invading cells grow rapidly and form their own blood vessels making them difficult to surgically remove or treat. GBM may develop de novo (primary) or through progression from a low-grade or anaplastic astrocytoma (secondary). Mutational inactivation of the p53 gene and presence of aberrant p53 expression are reported in GBM, suggesting that p53 has a role in tumor progression. This study of seven de novo GBM and four secondary GBM patients, indicated that nine out of eleven (82%) had overexpression of p53. Our histopathological analysis showed that the expression of p53 in three out of four (75%) secondary GBM was confined to the nucleus and the p53 positive cells were randomly distributed throughout the tumor. The expression of p53 in four out of seven (57%) de novo GBM was cytoplasmic, diffusive, and confined to the perivascular region of the tumor. In two (29%) de novo samples both nuclear as well as cytoplasmic staining that was not confined to the perivascular area was observed. The results suggest that cytoplasmic p53 may contribute to the formation and maintenance of de novo GBM by virtue of its control of the vasculature of tumors. Furthermore, cytoplasmic p53 may reflect an association of p53 with Cullin 7, PARC, or with the sequestering partner of p53, mortalin. These results underscore the significance of p53 in the tumorigenesis of de novo GBM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17214319

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  26 in total

1.  A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.

Authors:  Xishan Chen; Lingyu Tai; Jie Gao; Jianchang Qian; Mingfei Zhang; Beibei Li; Cao Xie; Linwei Lu; Wuyuan Lu; Weiyue Lu
Journal:  J Control Release       Date:  2015-09-30       Impact factor: 9.776

2.  TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.

Authors:  Dorota Jesionek-Kupnicka; Malgorzata Szybka; Beata Malachowska; Wojciech Fendler; Piotr Potemski; Sylwester Piaskowski; Dariusz Jaskolski; Wielislaw Papierz; Wieslaw Skowronski; Waldemar Och; Radzislaw Kordek; Izabela Zawlik
Journal:  DNA Cell Biol       Date:  2014-02-07       Impact factor: 3.311

Review 3.  To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.

Authors:  Bharathan Bhavya; C R Anand; U K Madhusoodanan; P Rajalakshmi; K Krishnakumar; H V Easwer; A N Deepti; Srinivas Gopala
Journal:  Cell Mol Neurobiol       Date:  2019-09-04       Impact factor: 5.046

4.  Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ.

Authors:  M Escoll; R Gargini; A Cuadrado; I M Anton; F Wandosell
Journal:  Oncogene       Date:  2017-02-06       Impact factor: 9.867

5.  Induction of apoptosis by cytoplasmically localized wild-type p53 and the S121F mutant super p53.

Authors:  Katsuhiro Yasuda; Shunsuke Kato; Yasuhiro Sakamoto; Gou Watanabe; Satsuki Mashiko; Atsuko Sato; Yuichi Kakudo; Chikashi Ishioka
Journal:  Oncol Lett       Date:  2012-02-29       Impact factor: 2.967

6.  Factors associated with increased survival after surgical resection of glioblastoma in octogenarians.

Authors:  Kalil G Abdullah; Ashwin Ramayya; Jayesh P Thawani; Lukasz Macyszyn; Maria Martinez-Lage; Donald M O'Rourke; Steven Brem
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

7.  A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.

Authors:  Sang-Soo Kim; Antonina Rait; Eric Kim; Kathleen F Pirollo; Maki Nishida; Natalia Farkas; John A Dagata; Esther H Chang
Journal:  ACS Nano       Date:  2014-05-15       Impact factor: 15.881

8.  A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.

Authors:  Alessia Garufi; Daniela Trisciuoglio; Manuela Porru; Carlo Leonetti; Antonella Stoppacciaro; Valerio D'Orazi; Maria Avantaggiati; Alessandra Crispini; Daniela Pucci; Gabriella D'Orazi
Journal:  J Exp Clin Cancer Res       Date:  2013-10-07

9.  Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line.

Authors:  Magdalena Kusaczuk; Rafał Krętowski; Marek Bartoszewicz; Marzanna Cechowska-Pasko
Journal:  Tumour Biol       Date:  2015-08-11

10.  Comparative transcriptomics reveals similarities and differences between astrocytoma grades.

Authors:  Michael Seifert; Martin Garbe; Betty Friedrich; Michel Mittelbronn; Barbara Klink
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.